Increasing the colon cancer cells sensitivity toward radiation therapy via application of Oct4–Sox2 complex decoy oligodeoxynucleotides

Johari, Behrooz; Rezaeejam, Hamed; Moradi, Mohammad; Taghipour, Zahraa; Saltanatpour, Zohreh; Mortazavi, Yousef; Nasehi, Leila

doi:10.1007/s11033-020-05737-4

Cited by 14 publications

(7 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are consistent with the role of decoy ODNs for inducing cell cycle arrest in the G1 phase in the previous studies. 58,59 In addition, apoptosis is the main reason for cell death induced by antitumor agents. Our data showed that the NISM@B-DEC can successfully induce apoptosis in the U87 cells, which may be related to modulating gene expression of NANOG pathway downstream genes.…”

Section: ■ Results and Discussionmentioning

confidence: 99%

NANOG Decoy Oligodeoxynucleotide–Encapsulated Niosomes Nanocarriers: A Promising Approach to Suppress the Metastatic Properties of U87 Human Glioblastoma Multiforme Cells

Gharbavi

Johari

Rismani

et al. 2020

ACS Chem. Neurosci.

Self Cite

View full text Add to dashboard Cite

Recently, advances in the synthesis and development of multifunctional nanoparticle platforms have opened up great opportunities and advantages for specifically targeted delivery of genes of interest. BSA-coated niosome structures (NISM@B) can potentially improve the efficiency in vitro delivery of nucleic acid molecules and the transfection of genes. Few studies have reported the combined use of niosomes with nucleic acid as therapeutic agents or decoy oligodeoxynucleotides (ODNs). Herein, we synthesized NISM@B to encapsulate NANOG decoy ODN (NISM@B-DEC), after which the physicochemical characteristics and in vitro and in vivo properties of NISM@B-DEC were investigated. Our results regarding physicochemical characteristics revealed that the stable niosome nanocarrier system was successfully synthesized with a regular spherical shape and narrow size distribution with proper zeta-potential values and had an appropriate biocompatibility. The ODN release from the niosome nanocarrier system exhibited controlled and pH-dependent behavior as the best models to explain the ODN release profile. NISM@B-DEC was efficiently taken up by human glioblastoma cells (U87) and significantly inhibited cell growth. Finally, blockage of the NANOG pathway by NISM@B-DEC resulted in G1 cell cycle arrest, apoptosis, and cell death. In addition, NISM@B-DEC caused a significant decrease in tumor formation and improved wound-healing efficiency of the U87 cells. These findings confirm that NISM@B-DEC could potentially suppress the metastatic ability of these cells. It can be concluded that the presented nanocarrier system can be a promising approach for targeted gene delivery in cancer therapy.

show abstract

Section: ■ Results and Discussionmentioning

confidence: 99%

NANOG Decoy Oligodeoxynucleotide–Encapsulated Niosomes Nanocarriers: A Promising Approach to Suppress the Metastatic Properties of U87 Human Glioblastoma Multiforme Cells

Gharbavi

Johari

Rismani

et al. 2020

ACS Chem. Neurosci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…This is particularly important in patients who have previously received two or more palliative lines of systemic chemotherapy, who often develop tumor cell resistance to chemotherapeutic agents following low sensitivity of cancer stem cells towards regular cancer therapy [ 18 , 19 ]. Understanding the mechanisms of cancer drug resistance is critical to allow the development of effective treatments with sustained anti-tumor effects [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of CRC-Metastatic Hepatic Lesion Chemoembolization with Irinotecan-Loaded Microspheres, According to the Site of Embolization

Szemitko

Golubinska-Szemitko

Warakomski

et al. 2022

JPM

View full text Add to dashboard Cite

With the chemembolization of colorectal-cancer (CRC)-metastatic hepatic lesions by irinotecan-loaded microspheres, most researchers recommend slow embolizate delivery at the lobar-artery level to the entire liver parenchyma without obtaining visible stasis. An association has been reported between postoperatively visible embolizate stasis and lesion response to treatment. Possibly, in some cases, more selective administration might give greater benefit, particularly with previous systemic chemotherapy failure. Objective: Treatment response evaluation after chemoembolization of CRC-metastatic liver lesions with irinotecan-loaded microspheres, according to a hepatic-artery branch level of administration. Patients and methods: The analysis included 54 patients (24 females, 30 males) with large (median diameter > 5 cm) CRC-metastatic liver lesions, who underwent 196 chemoembolization procedures (mean 3.63 per patient) with irinotecan (100 mg)-loaded microspheres. Patients were divided into two groups according to initial embolizate-administration branch level: Group A (n = 26): at the segmental or subsegmental-vessel level; Group B (n = 28): at the lobar-branch level. Treatment response was assessed by computed-tomography (mRECIST criteria); overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan–Meier method and adverse effects were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE; version 5.0). Results: There were statistically significant differences in the occurrence of partial response (PR): higher in Group A (42.3%) than Group B (17.9%) (p = 0.039) and occurrence of stable disease (SD): lower (p = 0.025) in Group A (11.5%) than Group B (39.4%). However, occurrence of disease progression (PD) was similar: Group A: 42.3%; Group B: 42.9% (p = 0.93). Patients in Group A presented with more favorable PFS (p = 0.029) and OS (p = 0.039) than Group B. Median survival times: Group A: 15.2 months; Group B: 13.1 months. There was no significant difference in complication incidence between groups (Group A: seven complications; Group B: six complications; p = 0.863). Conclusion: Superselective chemoembolizate administration to vessels supplying large CRC-metastatic liver lesions gave better response to treatment and extended patient survival time, without significantly increasing complication risk.

show abstract

“…In groups exposed to XI, MTX, and XI/MTX, STAT3 decoy ODNs reduced cell viability, halted growth at G0/G1, increased apoptosis rate, and decreased migrated and invaded cells via trans‐well membrane (Johari, Rahmati, et al, 2020). Another study aimed at elevating the sensitivity of cancer stem‐like cells toward radiotherapy by treating them with complex decoy oligodeoxynucleotides (ODNs; Johari, Rezaeejam, et al, 2020).…”

Section: Therapeutic Applications Of Pvnpsmentioning

confidence: 99%

Multifunctional plant virus nanoparticles: An emerging strategy for therapy of cancer

Azizi

Shahgolzari

Karkan

et al. 2022

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Cancer therapy requires sophisticated treatment strategies to obtain the highest success. Nanotechnology is enabling, revolutionizing, and multidisciplinary concepts to improve conventional cancer treatment modalities. Nanomaterials have a central role in this scenario, explaining why various nanomaterials are currently being developed for cancer therapy. Viral nanoparticles (VNPs) have shown promising performance in cancer therapy due to their unique features. VNPs possess morphological homogeneity, ease of functionalization, biocompatibility, biodegradability, water solubility, and high absorption efficiency that are beneficial for cancer therapy applications. In the current review paper, we highlight state‐of‐the‐art properties and potentials of plant viruses, strategies for multifunctional plant VNPs formulations, potential applications and challenges in VNPs‐based cancer therapy, and finally practical solutions to bring potential cancer therapy one step closer to real applications.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Biology‐Inspired Nanomaterials > Protein and Virus‐Based Structures

show abstract

Increasing the colon cancer cells sensitivity toward radiation therapy via application of Oct4–Sox2 complex decoy oligodeoxynucleotides

Cited by 14 publications

References 57 publications

NANOG Decoy Oligodeoxynucleotide–Encapsulated Niosomes Nanocarriers: A Promising Approach to Suppress the Metastatic Properties of U87 Human Glioblastoma Multiforme Cells

NANOG Decoy Oligodeoxynucleotide–Encapsulated Niosomes Nanocarriers: A Promising Approach to Suppress the Metastatic Properties of U87 Human Glioblastoma Multiforme Cells

Evaluation of CRC-Metastatic Hepatic Lesion Chemoembolization with Irinotecan-Loaded Microspheres, According to the Site of Embolization

Multifunctional plant virus nanoparticles: An emerging strategy for therapy of cancer

Contact Info

Product

Resources

About